VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.01320
Full Text
Open PDFAbstract
Available in full text
Date
January 30, 2020
Authors
Publisher
Frontiers Media SA